Protection against oncogenic non-vaccine types (cross-protection) offered by human papillomavirus (HPV) vaccines may provide a significant medical benefit. Available clinical efficacy data suggest the two licensed vaccines (HPV-16/18 vaccine, GlaxoSmithKline Biologicals (GSK), and HPV-6/11/16/18 vaccine, Merck & Co., Inc.) differ in terms of protection against oncogenic non-vaccine HPV types -31/45. The immune responses induced by the two vaccines against these two non-vaccine HPV types (cross-reactivity) was compared in an observer-blind study up to Month 24 (18 mo post-vaccination), in women HPV DNA-negative and seronegative prior to vaccination for the HPV type analyzed (HPV-010 [NCT00423046]). Geometric mean antibody titers (GMTs) measured by pseudovirion-based neutralization assay (PBNA) and enzyme-linked immunosorbent assay (ELISA) were similar between vaccines for HPV-31/45. Seropositivity rates for HPV-31 were also similar between vaccines; however, there was a trend for higher seropositivity with the HPV-16/18 vaccine (13.0-16.7%) versus the HPV-6/11/16/18 vaccine (0.0-5.0%) for HPV-45 with PBNA, but not ELISA. HPV-31/45 cross-reactive memory B-cell responses were comparable between vaccines. Circulating antigen-specific CD4+ T-cell frequencies were higher for the HPV-16/18 vaccine than the HPV-6/11/16/18 vaccine (HPV-31 [geometric mean ratio [GMR] =2.0; p=0.0002] and HPV-45 [GMR=2.6; p=0.0092]), as were the proportion of T-cell responders (HPV-31, p=0.0009; HPV-45, p=0.0793). In conclusion, immune response to oncogenic non-vaccine HPV types -31/45 was generally similar for both vaccines with the exception of T-cell response which was higher with the HPV-16/18 vaccine. Considering the differences in cross-protective efficacy between the two vaccines, the results might provide insights into the underlying mechanism(s) of protection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338933 | PMC |
| http://dx.doi.org/10.4161/hv.7.12.18282 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Monitoring the safety of the adjuvanted human papillomavirus vaccine, HPV-16/18-AS04: Protocol for a cohort study using electronic health records in Yinzhou, China.
Hum Vaccin Immunother
December 2024
Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
This protocol was developed to conduct population-wide surveillance of the bivalent HPV-16/18-AS04-adjuvanted human papillomavirus (HPV) vaccine in terms of uptake and safety outcomes including potential immune-mediated diseases (pIMDs) and pregnancy-related outcomes in China. The study will use electronic health records from 2010 to 2020 from the Yinzhou Regional Health Information Platform and include a population-based cohort of female permanent residents aged 9-45 years. Baseline and follow-up periods will be defined according to the 2017 introduction of HPV-16/18-AS04 in China.
View Article and Find Full Text PDFHPV16/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial.
J Natl Cancer Inst Monogr
November 2024
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Background: The Costa Rica HPV Vaccine Trial provided initial evidence that 1 dose of the bivalent human papillomavirus (HPV) vaccine induces stabilizing antibody levels that may provide extended protection against HPV-16/18 infections. We report antibody seropositivity and stability 11 to 16 years after vaccination.
Methods: We invited a random subset of Costa Rica HPV Vaccine Trial participants (n = 398) who had received 3 doses and all women (n = 203) who had received 1 dose at 18 to 25 years of age to follow-up visits 11, 14, and 16 years after vaccination.
Community intervention of a single-dose or 2-dose regimen of bivalent human papillomavirus vaccine in schoolgirls in Thailand: vaccine effectiveness 2 years and 4 years after vaccination.
J Natl Cancer Inst Monogr
November 2024
International Vaccine Institute, Seoul, Republic of Korea.
Article Synopsis
- A study was conducted in Thailand to compare the effectiveness of single-dose versus two-dose regimens of the HPV vaccine among 13-14 year old schoolgirls.
- The researchers assessed HPV prevalence among unvaccinated schoolgirls and compared it to vaccinated girls over a period of four years.
- Results showed a significant reduction in HPV prevalence among vaccinated girls, highlighting the potential effectiveness of a single-dose regimen.
Comparative study of triage strategies for women with atypical squamous cells of undetermined significance in the post-vaccine era.
Front Oncol
October 2024
Department of Public Health and Prevention, Changzhi Medical College, Changzhi, China.
Objective: The research focused on a comparative analysis of triage strategies for women with Atypical Squamous Cells of Undetermined Significance (ASC-US) before and after receiving the HPV vaccine, aiming to optimize cervical cancer prevention strategies, especially in resource-limited healthcare settings.
Materials And Methods: Between September 2018 and December 2023, 7,511 women aged 21 years or older who underwent liquid-based cytology for cervical cancer screening were recruited. Women diagnosed with ASC-US were included in the study.
High prevalence of human papillomavirus (HPV) in unvaccinated adolescent girls in South Africa, particularly those living with HIV.
Vaccine
December 2024
Wits RHI, University of the Witwatersrand, Johannesburg, Gauteng, South Africa. Electronic address:
Article Synopsis
- In 2014, South Africa launched an HPV vaccination program for girls aged 9 and older, but this study focused on 17-18 year old girls who weren't vaccinated, assessing HPV prevalence and related risk factors.
- From June to December 2019, the study surveyed adolescents at primary care clinics and collected data on HPV testing, HIV status, and sexual history from 900 participants, with a focus on understanding the link between these factors and HPV detection.
- Results showed that 56.5% had high-risk HPV, with a higher prevalence in those living with HIV, underscoring the need for increased HPV vaccination efforts in populations with high HIV rates.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!